The consortium of the RISK-IR project brings together expertise from 13 research groups of 10 institutions from 7 European countries.
Click on their name for further information and on their logo to reach the site of each insitution.
The Medical Research Council (MRC) is a publicly funded organization whose mission is to improve human health through research. The MRC Cancer Cell Unit (CCU) was founded in 2001 with the objective of undertaking world-leading laboratory research into cancer that can be translated into clinical practice to improve diagnosis and treatment.
The Unit now comprises seven research programmes led by a combination of basic and clinical investigators, with a focus epithelial preneoplasia in epithelia. The CCU is housed in the MRC-Hutchison Research Centre, which offers state of the art research facilities including the latest generation confocal imaging and flow cytometric cell sorting. Animal work will take place in the recently opened MRC ARES Building a new, facility to house breeding and experimental colonies of rodents in disease-free conditions. It provides for the highest standard of modern transgenic production services and experimental resources. The health and welfare of animals is a major priority for the MRC, and this philosophy has significantly influenced the design of the Ares Building to provide a disease-free and enriched cage environment for mice. A full health barrier excludes pathogenic organisms and ensures that the animals are of the highest health standard possible. Facilities include live imaging, mouse endoscopy and a radiation source for delivering low dose gamma radiation to mice.
Philip Jones leads a research program on stem cells and cancer in the MRC Cancer Cell Unit. His group is focused on the analysis of cell fate in epithelia and understanding how this changes following oncogenic mutation. He has pioneered the use of large scale cell lineage tracing in transgenic mice, drawing on approaches from statistical physics to quantify cell behavior in vivo and define how this changes following drug treatment and injury. The proposed studies in low dose radiation complement his MRC funded research on cell fate changes in early preneoplasia, for example exploring how p53 alters epidermal progenitor behavior in homeostatic and UV irradiated epidermis and the effects of oncogenic mutation on cell fate in esophageal epithelium.